NEW YORK (GenomeWeb) – GenMark Diagnostics reported today that its preliminary fourth quarter revenues rose approximately 21 percent year over year, thanks to an increase of about 110 percent in revenues from its ePlex analyzers during the quarter.

For the three months ended Dec. 31, 2018, the company said it expects total revenues of about $19.4 million, including ePlex revenues of approximately $12.1 million. Analysts, on average, are expecting total revenues of $18.8 million for the quarter.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.